ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need
Nitrofurantoin Oral Suspension USP is used to prevent and treat infections of the bladder, kidney and other parts of the urinary tract
ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Nitrofurantoin Oral Suspension USP, 25 mg/5 ml.
ANI’s Nitrofurantoin Oral Suspension is the generic version of the Reference Listed Drug (RLD) Furadantin® Oral Suspension 25 mg/5 ml.
The current annual U.S. market for Nitrofurantoin Oral Suspension is approximately $55.5 million, according to the latest estimates by IQVIA/IMS Health, a leading healthcare data and analytics provider.
"New product approvals and launches remain our top priority as we continue to grow our generics business. The FDA approval and commercialization of Nitrofurantoin Oral Suspension is another example of how we are continuing to bring limited-competition products to market, with the goal of serving the patient populations that can benefit,” stated Nikhil Lalwani, President and Chief Executive Officer of ANI.
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by building a successful Purified Cortrophin® Gel franchise, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities.
For more information, please visit our website www.anipharmaceuticals.com.
Source: ANI Pharmaceuticals
FC Global Strategies enables medical, pharma, healthcare, medical device and healthcare IT companies to achieve their business and financial goals
Since 1979 FC Global Strategies has enabled companies globally to achieve their business and financial objectives. If your company has business or financial objectives check out: 1. Strategic advisory services provided by FC Global Strategies 2. Medical and Pharma Insider’s AI Connect Marketing Program Click here to schedule a complimentary call to discuss your company's business and financial goals. Medical and Pharma Insider is a program of FC Global Strategies.
_________________________________ FC Global Strategies' Contacts North America and Latin America Jeffrey Friedland, +1 646 450 8909 Western Europe and the United Kingdom Leo Mattheos, +44 7308 083798 The Middle East, North Africa and Eastern Europe David Krutonog, +972 50 974 3429 Southeast Asia, Asia-Pacific, Australia, and New Zealand Ross Swan, +65 9181 9472